Tissue-Specific Vascular Endothelial Signals and Vector Targeting, Part A

Series-Editors.pdf......Page 2
Copyright.pdf......Page 3
List-of-Contributors.pdf......Page 4
Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature......Page 5
Introduction......Page 6
VEGF receptors......Page 7
Blocking VEGF/VEGFR binding......Page 8
VEGFR-specific and broad-spectrum TKIs induce rapid regression of tumor vasculature......Page 9
Posttreatment vascular resurgence and associated adverse effects of TKI treatment......Page 10
Using VEGFR-2 for Targeted Delivery of Powerful Toxic Agents......Page 12
Diphteria toxin......Page 13
Gelonin......Page 14
Shiga-like toxin......Page 15
Optimization of SLT-VEGF fusion protein for preclinical testing......Page 16
Dose/route selection for SLT-VEGF administration......Page 17
Prostate cancer model......Page 18
Pancreatic cancer model......Page 19
Mouse mammary carcinoma......Page 20
Systemic SLT-VEGF treatment targets endothelial cells with high levels of VEGFR-2 expression......Page 22
Treatment with sunitinib and SLT-VEGF......Page 24
References......Page 26
Adeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors......Page 32
Introduction......Page 33
AAV structure......Page 34
Infection and replicative cycle......Page 37
AAV-derived gene vectors......Page 39
AAV serotypes......Page 40
Chimeric and mosaic capsids......Page 41
Ligand-mediated receptor targeting......Page 42
Principle of random AAV-display libraries......Page 44
Different AAV peptide library technologies and further improvements•......Page 46
AAV peptide library screenings in vitro......Page 49
AAV peptide library screenings in vivo......Page 50
Other approaches for selection of tropism-modified AAV: Error-prone PCR, DNA shuffling, and multispecies libraries as alternative strategies
......Page 51
Ligand-directed AAV-phage hybrid vectors for targeted transgene delivery......Page 52
Perspectives......Page 53
References......Page 54
Tissue-Specific Targeting Based on Markers Expressed Outside Endothelial Cells......Page 64
Introduction......Page 65
Differentially expressed cell surface receptors as tissue markers and drug targets......Page 66
Organ-specific endothelial targets......Page 67
Organization of the vasculature and nonendothelial tissue access......Page 71
Nonendothelial Tissue-Specific Targets of Systemically Administered Agents......Page 72
Extracellular matrix markers......Page 76
Perivascular cell markers......Page 78
Interstitial stromal cell markers......Page 80
Parenchymal cell markers......Page 84
Hematopoietic cell markers......Page 88
Stem cell markers......Page 90
Concluding Remarks and Future Directions......Page 93
References......Page 95
Ligand-directed Cancer Gene Therapy to Angiogenic Vasculature......Page 106
Introduction......Page 107
Immunomodulation......Page 108
Prodrug-converting enzymes......Page 109
Tumor suppressor genes and antioncogenes......Page 110
Antiangiogenesis......Page 111
Vectors for Ligand-directed Gene Delivery......Page 112
Ligands for Targeting Angiogenic Vasculature......Page 115
References......Page 118
Subject-Index.pdf......Page 125